NEW YORK (GenomeWeb) – As it presses ahead with Phase II development of its flagship hepatitis B therapy ARC-520, Arrowhead Research is banking on the drug's ability to cut levels of the virus's surface antigen (s-antigen), a key indicator of active infection, the company's top executive said this week.

According to Arrowhead President and CEO Chris Anzalone, treating HBV has proven especially challenging because blocking viral replication alone is not enough to clear the virus, unlike with hepatitis C.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

In Science this week: reduction in bee phylogenetic diversity, and more.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.